Page 144 - 18F-FDG PET as biomarker in aggressive lymphoma; technical and clinical validation
P. 144
Chapter 6a
18. Maurer MJ, Habermann TM, Shi Q, et al. Progression-free survival at 24 months (PFS24) and subsequent outcome for patients with diffuse large B-cell lymphoma (DLBCL) enrolled on randomized clinical trials. Ann Oncol. 2018;29:1822–1827.
19. Burggraaff CN, de Jong A, Hoekstra OS, et al. Predictive value of interim positron emission tomography in diffuse large B-cell lymphoma: a systematic review and meta-analysis. Eur J Nucl Med Mol Imaging. 2019;46:65–79.
20. Toledano MN, Vera P, Tilly H, Jardin F, Becker S. Comparison of therapeutic evaluation criteria in FDG-PET/CT in patients with diffuse large-cell B-cell lymphoma: prognostic impact of tumor/liver ratio. PLoS One. 2019;14:e0211649.
21. Li X, Sun X, Li J, Liu Z, et al. Interim PET/CT based on visual and semiquantitative analysis predicts survival in patients with diffuse large B-cell lymphoma. Cancer Med. 2019;8:5012–5022.
22. Itti E, Meignan M, Berriolo-Riedinger A, et al. An international confirmatory study of the prognostic value of early PET/CT in diffuse large B-cell lymphoma: comparison between Deauville criteria and ∆SUVmax. Eur J Nucl Med Mol Imaging. 2013;40:1312–1320.
23. Rekowski J, Hüttmann A, Schmitz C, et al. Interim PET evaluation in diffuse large B-cell lymphoma employing published recommendations: comparison of the Deauville 5-point scale and the ∆SUVmax method. J Nucl Med. 2021;62:37–42.
24. Nols N, Mounier N, Bouazza S, et al. Quantitative and qualitative analysis of metabolic response at interim positron emission tomography scan combined with international prognostic index is highly predictive of outcome in diffuse large B-cell lymphoma. Leuk Lymphoma. 2014;55:773– 780.
25. Carr R, Fanti S, Paez D, et al. IAEA Lymphoma Study Group. Prospective international cohort study demonstrates inability of interim PET to predict treatment failure in diffuse large B-cell lymphoma. J Nucl Med. 201;55:1936–1944.
26. Mamot C, Klingbiel D, Hitz F, et al. Final results of a prospective evaluation of the predictive value of interim positron emission tomography in patients with diffuse large B-cell lymphoma treated with R-CHOP-14 (SAKK 38/07). J Clin Oncol. 2015;33:2523–2529.
27. Schöder H, Polley MY, Knopp MV, et al. Prognostic value of interim FDG-PET in diffuse large cell lymphoma: results from the CALGB 50303 clinical trial. Blood. 2020;135:2224–2234.
28. Schmitz C, Hüttmann A, Müller SP, et al. Supporting data for positron emission tomography based risk modelling using a fixed-instead of a relative thresholding method for total metabolic tumor volume determination. Data Brief. 2019;28:104976.
29. Vercellino L, Cottereau AS, Casasnovas O, et al. High total metabolic tumor volume at baseline predicts survival independent of response to therapy. Blood. 2020;135:1396-1405.
30. Le Gouill S, Ghesquières H, Oberic L, et al. Obinutuzumab vs rituximab for advanced DLBCL: a PET-guided and randomized phase 3 study by LYSA. Blood. 2021;137:2307-2320.
31. Sehn LH, Congiu AG, Culligan DJ, et al. No added benefit of eight versus six cycles of CHOP when combined with rituximab in previously untreated diffuse large B-cell lymphoma patients: results from the international phase III GOYA study. Blood. 2018;132:783.
32. Persky DO, Li H, Stephens DM. et al. Positron emission tomography–directed therapy for patients with limited-stage diffuse large B-cell lymphoma: results of intergroup national clinical trials Network Study S1001. J Clin Oncol. 2020;38:3003-3011.
142
